This is Okuzawa. Thank you for taking time out of your busy schedule to attend Daiichi Sankyo's Financial Results Presentation today. Now, I will explain the consolidated financial results for the ...

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) for breast cancer – Enhertu – which is tipped to become a multibillion-dollar ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will receive ...

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, ...

With an investment of approximately 1.1 billion yuan ($154 million), Daiichi Sankyo China broke ground on a new facility to produce antibody-drug conjugates (ADC) — an emerging class of highly potent ...

NEW YORK – The US Food and Drug Administration has accepted a supplemental biologics license application from AstraZeneca and Daiichi Sankyo seeking approval for an Enhertu (trastuzumab ...

Cancer remains one of Europe’s most pressing health challenges. According to the European Cancer Information System (ECIS), nearly one in four women and one in three men in Europe are expected to ...

A high-level overview of Daiichi Sankyo Company, Limited (DSKYF) stock. View (DSKYF) real-time stock price, chart, news, analysis, analyst reviews and more.

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the ...